KLRA Stock: Price, Earnings History and SEC Filings
Kailera Therapeutics, Inc. (KLRA) last traded at $12.86, down 4.10% on the latest session and up 12.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.09 against an analyst estimate of $-0.74, a miss of 47.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
KLRA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 12, 2026 | $-1.09 | $-0.74 | -47.30% |
KLRA beat the analyst EPS estimate in 0 of its last 1 reported quarters. Source: Nasdaq.
Latest SEC filings for KLRA
- 10-Q · Aug 12, 2026
- 8-K · Aug 12, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 26, 2026
- 8-K · May 26, 2026Results of operations, Financial statements and exhibits
- 8-K · Apr 20, 2026Bylaw change, Other events, Financial statements and exhibits
- 424B4 · Apr 17, 2026
- S-1 · Mar 27, 2026
Insider filing activity
KLRA insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
KLRA news
- Inhibikase Therapeutics Appoints Scott Wasserman to Board of DirectorsOct 20, 2026 · finance.yahoo.com
About Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. (KLRA) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.